Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
在該公司宣佈中國國家藥品監督管理局批准乙酰麴黴胺男ate片治療CLD相關血小板減少症之後，Gyre Therapeutics股票價格上漲。
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
在該公司宣佈中國國家藥品監督管理局批准乙酰麴黴胺男ate片治療CLD相關血小板減少症之後，Gyre Therapeutics股票價格上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。